An analysis of several multigene breast cancer recurrence signatures suggests that some tests may be better than others at assessing risk of late distant recurrence.
Although a draft guidance last month recommended against use of molecular tests to guide chemotherapy, the group's finalized decision is subject to price negotiation and other adjustments.
An assessment concluded that Oncotype Dx has not demonstrated a significant enough impact on outcomes or cost effectiveness compared to current practice.
Companies in the life science tools and molecular diagnostics spaces provided updates on their businesses at the 36th annual JP Morgan Healthcare Conference this week in San Francisco.
The Index underperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index, reversing gains it had made in October and November.
The investment bank previously had a Neutral rating for the company, and it lowered the price target on Genomic Health's stock to $25 from $28.
Genomic Health will test samples from Janssen prostate cancer drug studies to examine whether its test can predict patient outcomes.
The firm said it raised €80 million to fund an expansion of, and new applications for, the Idylla test menu.
The company discussed expectations for how its products will fare against rivals into next year based on recent data and coverage decisions, and on expected reimbursement changes.
Test volume was up 5 percent, but the company's total revenue of $83.8 million was negatively affected by hurricanes in the US, company executives said.
The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.
Nobel laureate Günter Blobel has died at 81, the New York Times reports.
In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.